NYSTATIN ORAL SUSPENSION, USP

Manufacturer
Preferred Pharmaceuticals Inc.
Effective date
2026-10-09
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
4
Source
daily-update
Hydrated at
2026-10-13 04:07:52

Label at a glance#

ProductNYSTATIN
Active ingredientNYSTATIN
Label structure12 sections

Indications and uses

Nystatin oral suspension is indicated for the treatment of infections of the oral cavity caused by Candida albicans.

Dosage and administration

Infants: 2 mL (200,000 units) four times daily (1 mL in each side of mouth). Pediatric patients and adults: 4 to 6 mL (400,000 to 600,000 units) four times daily (one-half of dose in each side of mouth). NOTE: Limited clinical studies in neonates, including premature and low-birth weight neonates, indicate that 1 mL (100,000 units) four times daily is effective. Local treatment should be continued at least 48 hour...

Label contents#

Full prescribing information#

DESCRIPTION

DESCRIPTION SECTION

Nystatin is obtained from Streptomyces noursei. It is known to be a mixture, but the composition has not been completely elucidated. Nystatin A is closely related to amphotericin B. Each is a macro-cyclic lactone containing a ketal ring, an all-trans polyene system, and a mycosamine (3-amino-3-deoxyrhamose) moiety.
Structural formula:

chemstructure
chemstructure

Nystatin Oral Suspension, for oral administration, contains 100,000 USP Nystatin Units per mL. Inactive ingredients: alcohol (≤ 1% v/v), sucrose 50% w/v, peppermint oil, NF, cinnamaldehyde, disodium hydrogen phosphate, USP, carboxymethylcellulose sodium, USP, glycerin, USP, saccharin sodium, USP, cherry flavor, methylparaben, NF, propylparaben, NF and purified water, USP. May also contain sodium hydroxide, NF and/ or hydrochloric acid, NF for pH adjustment.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Nystatin acts by binding to sterols in the cell membrane of the fungus with a resultant change in membrane permeability allowing leakage of intracellular components. Nystatin is absorbed very sparingly following oral administration, with no detectable blood levels when given in the recommended doses.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Nystatin oral suspension is indicated for the treatment of infections of the oral cavity caused by Candida albicans.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Nystatin is contraindicated in patients with a history of hypersensitivity to nystatin or any of the suspension components.

PRECAUTIONS

PRECAUTIONS SECTION

General
Discontinue treatment with nystatin if sensitization or irritation is reported during use.
Nystatin is not effective in the treatment of systemic mycoses since it is not significantly absorbed from the gastrointestinal
tract.

Information for the Patient
Patient should be advised to retain nystatin in the mouth as long as possible and to continue its use for at least 2 days after symptoms have subsided.

There should be no interruption or discontinuation of the medication until the prescribed course of treatment is completed, even though symptomatic relief may occur within a few days.
If symptoms of local irritation develop, the physician should be notified immediately.

Laboratory Tests
If there is a lack of therapeutic response, appropriate microbiological studies (e .g., KOH smears and/or cultures) should be repeated to confirm the diagnosis of candidiasis and rule out other pathogens before instituting another course of therapy.

Carcinogenesis, Mutagenesis, Impairment of Fertility
No long-term animal studies have been performed to evaluate the carcinogenic potential of nystatin. In mice exposed to nystatin 50 mg/kg by injection, an increased incidence of chromosomal aberrations, consisting primarily of chromatid breaks, was observed in bone marrow cells. However, there have been no studies to determine the mutagenicity of orally-administered nystatin or its effects on fertility in males or females.

Pregnancy:

Teratogenic Effects
Teratogenicity studies have not been conducted with nystatin. It is also not known whether nystatin can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Nystatin should be given to a pregnant woman only if clearly needed.

Nonteratogenic Effects
In one rat reproductive study, nystatin was administered orally to pregnant rats in single doses of 100, 500, or 3000 mg/kg on the ninth day of gestation, or as multiple doses of 500 mg/kg/day on gestation days 1-20, 1-4, 7-10, 11-14, or 15-18. It was found that nystatin had a slight abortive effect when used during the whole period of pregnancy. No abnormalities were seen in surviving fetuses. Although no adverse effects or complications have been attributed to the use of intra-vaginal nystatin in neonates born to women treated during pregnancy, no similar studies evaluating complications of oral nystatin have been conducted.

Nursing Mothers
It is not known whether nystatin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when nystatin is administered to a nursing woman.

Pediatric Use
See DOSAGE AND ADMINISTRATION section for pediatric dosing recommendations.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

To report SUSPECTED ADVERSE REACTIONS, contact FDA at 1-800-FDA-1088 OR LEADING PHARMA, LLC AT 1-844-740-7500 or www.fda.gov/medwatch.

Gastrointestinal symptoms including diarrhea, gastrointestinal distress, nausea, vomiting and burning of the mouth have been reported. Hypersensitivity reactions including rash, pruritus, and anaphylactoid reaction have also been reported.

OVERDOSAGE

OVERDOSAGE SECTION

Oral doses of nystatin in excess of five million units daily have caused nausea and gastrointestinal upset.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Infants: 2 mL (200,000 units) four times daily (1 mL in each side of mouth).

Pediatric patients and adults: 4 to 6 mL (400,000 to 600,000 units) four times daily (one-half of dose in each side of mouth).

NOTE: Limited clinical studies in neonates, including premature and low-birth weight neonates, indicate that 1 mL (100,000 units) four times daily is effective.

Local treatment should be continued at least 48 hours after perioral symptoms have disappeared and/or cultures returned to normal. It is recommended that the drug be retained in the mouth as long as possible before swallowing.

CAUTION

SPL UNCLASSIFIED SECTION

The Packaging of This Product Contains Natural Rubber Latex Which May Cause Allergic Reactions

HOW SUPPLIED

HOW SUPPLIED SECTION

Nystatin Oral Suspension, USP, 100,000 USP Nystatin Units per mL, is available as a cherry-mint flavored, light creamy yellow, ready-to-use suspension, in the following sizes: 60 mL bottles with a child-resistant cap and calibrated dropper.
1 Pint (473 mL) bottles with a child-resistant cap.

NDC for 473 ml: 68788-8561-4

NDC for 60 ml: 68788-8561-6

Storage
This package is child-resistant. Keep out of reach of children. Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Avoid freezing


NDC for 473 ml: 68788-8561-4

NDC for 60 ml: 68788-8561-6

Rx Only

SPL UNCLASSIFIED SECTION

Manufactured by:

Medley Pharmaceuticals Ltd.

Plot No. 18 and 19, Survey No. 378 / 7 & 8, 379 / 2 & 3,

Zari Causeway Road, Kachigam, Daman - 396210, INDIA.

Distributed by:

Leading Pharma, LLC

3 Oak Rd, Fairfield,.

New Jersey (NJ) 07004, United States (USA)

REV. 03/22                                                P000324

Relabeled By: Preferred Pharmaceuticals Inc.

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Nystatin Oral Suspension USP
Nystatin Oral Suspension USP

Product Linked Resources#

Resource, Code type, Value table
ResourceCode typeValueEquivalent identifiersSource image
Data codeCode 128230containerlabel-60ml.jpg
Data codeData Matrix**082925*containerlabel-60ml.jpg

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
e29fe634-dc25-094c-c77f-5d09c3eceb3eProduct name520260107
726062af-1135-4707-a1d7-57256991bbf9Product name220250226
e57b6340-9387-3f9a-7307-511c81791375Product name320221214
544f8e8d-6389-eeeb-9586-aa447c08dcc7Product name520210614
1629e00f-54fb-4a43-8306-b58442b23902Product name920200430
854ec07b-1cd7-a5db-235a-7aa24d3cf97aProduct name320180628
19b9f4c1-15e9-edcc-4c16-f01ecfb5c549Product name120140508
19c71a3d-ed9c-166b-a7e5-38c250c35631Product name120140508

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
68788-8561-4ML - Milliliter68788-856195415b6f-e597-4db3-aed3-1deb9dfdac6a12024-05-16
69315-504-47ML - Milliliter69315-5047ee88db7-6fae-40eb-86e6-51df053fd4fa12023-01-09
69315-504-60ML - Milliliter69315-5049e804b7e-9bfd-4abc-b5b2-d6e7fc37fe1812023-01-09

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 14 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
68788-856168788-8561-4, 68788-8561-6
69315-504

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 14 matching rows.

Source Document#

Source XML

Older Hydrated Versions#

Version, Effective date, Source table
VersionEffective dateSourceHydrated
32026-08-05daily-update2026-08-08 02:04:51
22025-08-29full-release2026-05-31 21:41:29

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 45.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A214346-001NYSTATINNYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS2022-03-10

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
A214346-001AA

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-11-14 07:37:172026-10A214346-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS2022-03-10d4dbc9d85df4…
2026-10-15 13:18:302026-09A214346-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS2022-03-10c2088c7a36db…
2026-09-14 22:38:342026-08A214346-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS2022-03-1084e616aacf4f…
2026-08-18 06:07:402026-07A214346-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS2022-03-10caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A214346-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS2022-03-10011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A214346-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS2022-03-1031067a03dcf5…
2025-08-23 18:47 UTC2025-08A214346-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS2022-03-106a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A214346-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS2022-03-10fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A214346-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS2022-03-10b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A214346-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS2022-03-1003ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A214346-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS2022-03-102680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A214346-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS2022-03-105bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A214346-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS2022-03-10d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A214346-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS2022-03-10d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A214346-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS2022-03-1079d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A214346-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2022-03-10301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A214346-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2022-03-101e350fbaab3a…
2024-05-31 18:47 UTC2024-05A214346-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2022-03-108072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A214346-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2022-03-105c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A214346-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2022-03-105d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A214346-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2022-03-104b0b4de00fa7…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A214346-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2022-03-106a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A214346-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2022-03-101c564ffb4f44…
2023-12-20 04:57 UTC2023-12A214346-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2022-03-10ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A214346-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2022-03-10a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A214346-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2022-03-109b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A214346-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2022-03-10a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A214346-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2022-03-103f0d92c62455…
2023-05-13 08:27 UTC2023-05A214346-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2022-03-10053a50430f4f…
2023-01-26 05:58 UTC2023-01A214346-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2022-03-103bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A214346-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2022-03-103a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A214346-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2022-03-10f41ea6bd6efb…
2022-09-29 23:25 UTC2022-09A214346-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2022-03-10e64feba35796…
2022-07-09 03:26 UTC · 3 captures of this ZIP2022-07A214346-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2022-03-10cb3db0bc1861…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06A214346-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS2022-03-10a50c72e98297…

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-11-14 07:37:172026-10A214346-001AA1d4dbc9d85df4…
2026-10-15 13:18:302026-09A214346-001AA1c2088c7a36db…
2026-09-14 22:38:342026-08A214346-001AA184e616aacf4f…
2026-08-18 06:07:402026-07A214346-001AA1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A214346-001AA1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A214346-001AA131067a03dcf5…
2025-08-23 18:47 UTC2025-08A214346-001AA16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A214346-001AA1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A214346-001AA1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A214346-001AA103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A214346-001AA12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A214346-001AA15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A214346-001AA1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A214346-001AA1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A214346-001AA179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A214346-001AA1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A214346-001AA11e350fbaab3a…
2024-05-31 18:47 UTC2024-05A214346-001AA18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A214346-001AA15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A214346-001AA15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A214346-001AA14b0b4de00fa7…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A214346-001AA16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A214346-001AA11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A214346-001AA1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A214346-001AA1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A214346-001AA19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A214346-001AA1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A214346-001AA13f0d92c62455…
2023-05-13 08:27 UTC2023-05A214346-001AA1053a50430f4f…
2023-01-26 05:58 UTC2023-01A214346-001AA13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A214346-001AA13a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A214346-001AA1f41ea6bd6efb…
2022-09-29 23:25 UTC2022-09A214346-001AA1e64feba35796…
2022-07-09 03:26 UTC · 3 captures of this ZIP2022-07A214346-001AA1cb3db0bc1861…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06A214346-001AA1a50c72e98297…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 2 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
NYSTATINNYSTATINPreferred Pharmaceuticals Inc.8211a0ef-98a8-4136-986c-23c306db11592026-10-09Adverse reactionsExact identifier
ndc (package): 68788-8561-4
ndc (package): 68788-8561-6
ndc (product): 68788-8561
ndc11 (package): 68788856106
ndc11 (package): 68788856104
spl id: bf047ee0-bcba-42cf-b968-aa5088eff729
spl set id: 8211a0ef-98a8-4136-986c-23c306db1159
NYSTATINNYSTATINLeading Pharma, LLC954205d8-47ba-4c89-95cd-f0066a514cf92024-11-28Adverse reactionsExact identifier
ndc (product): 69315-504

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.